Avestar Capital’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.61M | Sell |
14,349
-413
| -3% | -$88.9K | 0.2% | 87 |
|
|
2026
Q1 | $3.21M | Buy |
14,762
+45
| +0.3% | +$9.98K | 0.21% | 80 |
|
|
2025
Q4 | $3.36M | Buy |
14,717
+245
| +2% | +$55.8K | 0.22% | 79 |
|
|
2025
Q3 | $3.35M | Sell |
14,472
-1,246
| -8% | -$254K | 0.22% | 83 |
|
|
2025
Q2 | $2.92M | Buy |
15,718
+2,197
| +16% | +$408K | 0.2% | 87 |
|
|
2025
Q1 | $2.83M | Buy |
13,521
+655
| +5% | +$127K | 0.25% | 79 |
|
|
2024
Q4 | $2.29M | Buy |
12,866
+1,413
| +12% | +$260K | 0.19% | 92 |
|
|
2024
Q3 | $2.26M | Sell |
11,453
-33
| -0.3% | -$6.16K | 0.23% | 79 |
|
|
2024
Q2 | $1.97M | Buy |
11,486
+868
| +8% | +$144K | 0.2% | 93 |
|
|
2024
Q1 | $1.93M | Buy |
10,618
+1,834
| +21% | +$316K | 0.2% | 97 |
|
|
2023
Q4 | $1.36M | Buy |
8,784
+1,328
| +18% | +$194K | 0.15% | 88 |
|
|
2023
Q3 | $1.11M | Buy |
7,456
+1,916
| +35% | +$281K | 0.16% | 85 |
|
|
2023
Q2 | $746K | Sell |
5,540
-1,601
| -22% | -$235K | 0.12% | 108 |
|
|
2023
Q1 | $1.14M | Buy |
7,141
+738
| +12% | +$113K | 0.2% | 63 |
|
|
2022
Q4 | $1.03M | Buy |
6,403
+684
| +12% | +$105K | 0.19% | 73 |
|
|
2022
Q3 | $768K | Buy |
5,719
+28
| +0.5% | +$4.02K | 0.2% | 78 |
|
|
2022
Q2 | $872K | Buy |
5,691
+554
| +11% | +$84.7K | 0.21% | 72 |
|
|
2022
Q1 | $833K | Buy |
5,137
+991
| +24% | +$144K | 0.13% | 148 |
|
|
2021
Q4 | $561K | Sell |
4,146
-89
| -2% | -$10.5K | 0.07% | 238 |
|
|
2021
Q3 | $457K | Sell |
4,235
-3,979
| -48% | -$455K | 0.06% | 285 |
|
|
2021
Q2 | $925K | Sell |
8,214
-882
| -10% | -$99.3K | 0.12% | 195 |
|
|
2021
Q1 | $1.02M | Buy |
9,096
+923
| +11% | +$98.7K | 0.23% | 96 |
|
|
2020
Q4 | $876K | Buy |
8,173
+648
| +9% | +$62.3K | 0.24% | 78 |
|
|
2020
Q3 | $631K | Sell |
7,525
-2,358
| -24% | -$222K | 0.21% | 101 |
|
|
2020
Q2 | $970K | Buy |
9,883
+2,423
| +32% | +$213K | 0.43% | 62 |
|
|
2020
Q1 | $568K | Buy |
7,460
+4,401
| +144% | +$375K | 0.31% | 81 |
|
|
2019
Q4 | $270K | Sell |
3,059
-331
| -10% | -$27.5K | 0.15% | 127 |
|
|
2019
Q3 | $257K | Buy |
3,390
+1,100
| +48% | +$75.4K | 0.16% | 119 |
|
|
2019
Q2 | $160K | Buy |
2,290
+130
| +6% | +$10.2K | 0.1% | 135 |
|
|
2019
Q1 | $168K | Buy |
2,160
+566
| +36% | +$46.3K | 0.11% | 131 |
|
|
2018
Q4 | $143K | Sell |
1,594
-486
| -23% | -$42.7K | 0.1% | 127 |
|
|
2018
Q3 | $191K | Buy |
2,080
+303
| +17% | +$28.7K | 0.11% | 126 |
|
|
2018
Q2 | $158K | Buy |
1,777
+27
| +2% | +$2.64K | 0.1% | 133 |
|
|
2018
Q1 | $161K | Sell |
1,750
-223
| -11% | -$24.5K | 0.1% | 118 |
|
|
2017
Q4 | $184K | Buy |
+1,973
| New | +$186K | 0.14% | 85 |
|
Other funds holding ABBV
ECSS
ATO
Avestar Capital's ABBV Position: Q2 2026 in Review
Avestar Capital reduced its AbbVie (ABBV) stake by 2.8% in Q2 2026, selling an estimated $88.9K and leaving 14,349 shares worth $3.61M. The position accounts for 0.2% of the portfolio, ranked #87.
Avestar Capital first reported a position in ABBV in Q4 2017 and has held it in 35 quarters since. 2,093 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Avestar Capital held 14,349 shares of AbbVie worth $3.61M as of Q2 2026.
- Avestar Capital sold 413 AbbVie shares in Q2 2026, an estimated $88.9K.
- AbbVie made up 0.2% of Avestar Capital's portfolio in Q2 2026, its #87 holding.
- Avestar Capital first reported a position in AbbVie in Q4 2017 and has held it in 35 quarters since.
- 2,093 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Avestar Capital's 13F filing for Q2 2026, filed 29 Jul 2026.